Biologically Synthesized Hydroxyapatite for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing hydroxyapatite (HAP) face challenges such as low crystallinity, high porosity, and heterogeneity, which affect its mechanical strength and bioactivity, and existing methods for producing HAP are laborious and inefficient, particularly for use in bone regeneration and implant applications.
Innovation Solution
The method involves contacting cells with calcium and an acyclic alkane phosphoester salt or inorganic phosphate salt to produce HAP, either by expressing alkaline phosphatase or genetically engineering cells to do so, allowing for efficient production of crystalline HAP with controlled particle size, which can be harvested or used to coat objects like medical devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional wet chemical precipitation techniques are used to synthesize hydroxyapatite, then the synthesis process is simple and scalable, but the resulting HAP has low crystallinity, high porosity, and heterogeneity which reduce mechanical strength and bioactivity
Solution Approach 1:
The patent uses alkaline phosphatase enzyme as an intermediary catalyst to mediate the precipitation of hydroxyapatite from calcium and phosphate precursors. This biological intermediary enables controlled nucleation and crystal growth, producing HAP with high crystallinity and uniform morphology while maintaining process simplicity. The enzyme facilitates the transformation from amorphous precipitates to crystalline structure without requiring complex multi-step synthesis procedures.
Solution Approach 2:
The patent employs parameter changes by controlling pH levels (using Tris-HCl buffer at pH 7.4), temperature (37°C), and ion concentrations (calcium and phosphate salts) to optimize HAP crystallization. These controlled parameter variations enable the system to transition from amorphous to crystalline state, improving manufacturing precision while keeping the overall process simple and scalable for industrial production.
2Productivity
If conventional HAP synthesis methods are used, then production is relatively fast, but the material lacks superior bioactivity and biocompatibility required for effective bone regeneration
Solution Approach 1:
The patent applies self-service by using cells (such as osteoblasts or stem cells) that naturally possess the ability to synthesize hydroxyapatite as the production system. The cells themselves provide the enzymatic machinery (alkaline phosphatase) and biological control mechanisms needed for producing bioactive HAP, eliminating the need for external complex synthesis equipment. This biological self-service ensures superior bioactivity and biocompatibility while maintaining efficient production rates through cellular metabolism.
Solution Approach 2:
The patent replaces mechanical/chemical synthesis systems with a biological system based on cellular metabolism and enzymatic catalysis. Instead of using high-energy chemical precipitation or thermal processing, the invention uses biological mechanisms (alkaline phosphatase enzyme catalysis, cellular mineralization pathways) to produce HAP. This substitution inherently improves bioactivity and biocompatibility while maintaining productivity through efficient cellular processes.
3Reliability
If autograft bone is used to fill bone defects, then the material has excellent biocompatibility and osteoconductivity, but supply is limited and donor site pain or hemorrhage occurs
Solution Approach 1:
The patent creates a copy of natural bone material by producing hydroxyapatite through cellular biomineralization processes. Instead of using actual autograft bone which is limited by donor availability, the system copies the essential functional properties (crystalline structure, bioactivity, osteoconductivity) through controlled cellular production. This allows unlimited supply while maintaining the excellent biocompatibility and osteoconductivity of natural bone, eliminating donor site morbidity.
Solution Approach 2:
The patent uses parameter changes in cell culture conditions (pH, temperature, ion concentrations, growth factors) to optimize the production of bioactive HAP that mimics natural bone. By carefully controlling these parameters, the system produces HAP with identical crystalline structure and surface properties to autograft bone, achieving the same biocompatibility and osteoconductivity without the limitations of donor availability and surgical complexity.
4Ease of manufacture
If allograft bone is used to fill bone defects, then supply is abundant, but immune-mediated rejection and transmission of infectious diseases occur
Solution Approach 1:
The patent extracts and isolates the essential functional component of bone (hydroxyapatite mineral) from the complex biological system, producing it through controlled cellular processes. This extraction approach allows the material to be produced aseptically in controlled environments, eliminating risks of immune rejection and infection transmission associated with allografts. The extracted mineral can be sterilized and stored without preserving donor-specific antigens or pathogens, while maintaining abundance of supply.
Solution Approach 2:
The patent replaces the mechanical process of harvesting and processing donor bone with a biological synthesis system using cellular metabolism. This substitution eliminates the need for donor organs, thereby removing the risks of immune-mediated rejection and infectious disease transmission. The system produces abundant amounts of bioactive HAP through scalable cellular culture techniques, maintaining availability while eliminating harmful factors inherent in allograft transplantation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of HAP with superior crystallinity and bioactivity, overcoming the limitations of traditional methods by providing a biocompatible and bioresorbable material suitable for bone regeneration and implant applications.
Implementation Method 1
contacting cells with calcium and an acyclic alkane phosphoester salt or inorganic phosphate salt to produce HAP, either by expressing alkaline phosphatase or genetically engineering cells to do so
Implementation Method 2
The induction of osteoblast differentiation was previously considered the essential first step of biomineralization. However, both the morphology and gene expression profile of osteoblasts are similar to those of fibroblasts, and there is no evidence suggesting that biomineralization is orchestrated by specific genes expressed in osteoblasts
Implementation Method 3
Groups of osteoblasts use calcium and inorganic phosphorus to produce the crystalline mineral hydroxyapatite (HAP). These calcium phosphate nanocrystals are deposited in a collagen matrix to harden bones in a process known as biomineralization
Data Source
AI summary
Herein the inventors demonstrate that mineralization is a natural ability of cells cultured with at least two elements: calcium and acyclic alkane phosphoester salt or inorganic phosphate salt. The present invention provides methods for producing hydroxyapatite (HAP) in cell culture by supplying cells with these elements. The natural HAP crystals produced by these methods may be utilized in biomedical applications such as bone grafting. Also provided are methods of measuring organic phosphates in a sample from a subject and methods of measuring the glycerophosphates in a sample from a subject.